Allele’s Proven Cannabis Cultivar Collection

VANCOUVER, (March 10, 2021) Segra International Corp. and Allele Genetics, a subsidiary of Catalyst BC, are pleased to announce they have entered into an exclusive agreement to distribute Allele’s collection of data-backed “Proven Cultivar” cannabis cultivars within the Canadian market and other legal international markets. Allele’s Proven Cultivars have been grown at both a commercial scale and for breeding and agronomic dataset development for over a decade by one of the most experienced operational teams in the industry, Catalyst BC, and its affiliates. Harnessing the strength of its proven Plant Tissue Culture technology, Segra will be releasing Allele cultivars on an ongoing basis as part of its Verified Clean Stock program.

Allele’s Proven Culticars have been carefully selected based on cannabinoid profile and yield, terpene profiles, and key characteristics such as maturation cycle time, high-density trichome area index (“TAI”), mold/mildew resistance and high bract-to-leaf ratios. The ongoing cultivar releases will represent abroad palate of terpene profiles yielding flavors and aromas ranging from citrus to berry and cake to gas–flavors the modern cannabis consumer desires. Amplifying Allele’s Proven Winners with the power of Segra’s tissue culture technologies will ensure consistently high-performing plants that are, as with all Segra tissue culture plants, Verified Clean Stock. Segra and Allele are confident that this offering will help producers turn better plants into better profits.

“Segra is thrilled to be partnering more closely with Allele and able to offer a portion of their data-backed collection, through tissue culture, to operators,” said Segra CEO Jamie Blundell. “Allele has developed an incredible portfolio of diverse, premium cannabis cultivars through tremendous industry expertise and experience. Partnering with top genetics consultants, like Allele Genetics, is central to Segra’s ability to continuously provide our clients with the cultivars of the future, and we are keen to showcase how top genetics, paired with the performance of tissue culture, will lead to operational optimization for Canadian LPs.”

“Today’s cannabis consumer desires potency, flavor, and aroma. Allele’s Proven Cultivars is a collective team effort to enhance and elevate the evolving consumer experience. We have spent the better part of a decade collecting critical agronomic data and consumer feedback necessary to drive cannabis cultivar identification, selection, collection, trialing, and optimization.” Said Eric Forington, Director of Plant Breeding and Genetics at Allele Genetics. Our primary goal is an emphasis on both consumer experience, through consistently high-quality, high-potency, flavor and aroma-forward flower, and LP success by allowing superior genetics to do the heavy agronomic lifting. We are incredibly excited to support the distribution of our Proven Cultivars in the Canadian and legal global import/export markets through Segra’s proprietary micropropagation process and look forward to partnering with Segra to provide true-to-type, commercially viable plantlets at scale.”

Segra is an agriculture technology company offering plant tissue culture and DNA fingerprinting services to accelerate the advancement of the cannabis industry. The company’s proprietary technologies empower its clients to drive financial performance and mitigate risk while exploring the next frontier of optimized cultivation practices for the rapidly evolving cannabis consumer. Segra has developed industrial-scale laboratories to produce disease-free, robust, and DNA-fingerprinted cannabis plantlets for licensed producers globally. To support this vision, Segra has assembled a world-class team of specialists in the fields of agronomy, molecular genetics, plant tissue culture, and regulatory compliance. Learn more about Segra here.

For Further Information:

Carson Otto

Carson.otto@segra-intl.com

Forward-Looking Information:

This news release includes statements containing certain “forward-looking information” within the meaning of applicable securities law (“forward-looking statements”). Forward-looking statements are frequently characterized by words such as “plan,” “continue,” “expect,” “project,” “intend,” “believe,” “anticipate,” “estimate,” “may,” “will,” “potential,” “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks, uncertainties, and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The company is under no obligation and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as expressly required by applicable law.

Additional Resources

Consulting Services For Cannabis, Hemp, Psilocybin, and Natural Medicine

Testimonials and Public Relations

Latest Articles

Colorado Psilocybin License Application: The Definitive Guide
With Colorado’s regulated psilocybin program now in effect, exciting opportunities await entrepreneurs, facilitators, and businesses in the state’s natural medicine market. Whether your goal is to open a healing center, cultivate psilocybin, or become a licensed facilitator, our comprehensive guide to obtaining a Colorado Psilocybin License is here to help you every step of the way.
Tennessee Cannabis Legalization 2025: Medical and Adult-Use Reform Efforts Overview
The Tennessee General Assembly is witnessing a renewed push for cannabis reform in 2025. Lawmakers have introduced bicameral legislation to legalize both medical and adult-use cannabis. However, the effort remains highly partisan, with competing proposals and legislative hurdles posing significant challenges.
Iowa Cannabis Legalization 2025: Incremental Steps Toward Expansion and Reform
Iowa’s medical cannabis program remains one of the most restrictive in the country, to the extent that some advocacy groups do not even recognize it as a legitimate cannabis market. With stringent limitations on product availability, patient access, and dispensary operations, the state’s program offers minimal relief compared to more robust medical cannabis frameworks elsewhere. However, with several reform bills in play this session, Iowa may see incremental changes in 2025.
Indiana Cannabis Legalization 2025: Lawmakers Push for Reform Amid Legislative Roadblocks
Indiana Cannabis Legalization remains a complex and uphill battle despite growing bipartisan support for medical cannabis reform. While Indiana lawmakers continue to push for legalization efforts, 2025 is shaping up to be another year of legislative stagnation as Republican leaders block cannabis-related bills from advancing.
Virginia Cannabis Legalization 2025: Stuck in Limbo Under Youngkin’s Veto Power
Virginia Cannabis Legalization remains in a state of limbo. While adults 21 and older can legally grow, possess, and consume cannabis, they have no legal avenue to purchase it within the state. This predicament stems from a 2021 legalization bill signed by former Democratic Gov. Ralph Northam, which required reenactment to establish a regulated market. However, Republican Gov. Glenn Youngkin’s opposition to cannabis reform has stalled further progress.
Texas Cannabis Reform 2025: The Push for Meaningful Legislation
Texas Cannabis Reform remains a hot-button issue in 2025 as lawmakers debate the state’s restrictive medical cannabis program, the booming hemp-derived THC market, and potential pathways for broader legalization. Despite overwhelming public support for cannabis reform, legislative action remains uncertain in the Lone Star State.